Functional studies have shown that downregulation of NR2F1-AS1 can attenuate the malignant phenotype of dormant breast cancer cells and sensitize them to chemotherapeutic agents, thereby improving therapeutic efficacy [26, 27]. This evidence concerns the gene NR2F1 and breast cancer.